Intensity Therapeutics Publishes Promising Phase 1/2 Results for Novel Cancer Drug INT230-6
Study in eBioMedicine shows strong disease control and survival benefits across multiple tumor types with minimal toxicity Intensity Therapeutics (INTS), ...
Study in eBioMedicine shows strong disease control and survival benefits across multiple tumor types with minimal toxicity Intensity Therapeutics (INTS), ...
© 2024 All Rights Reserved: STOXPO.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information
Do you really wish to opt-out?